JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

Search

CytomX Therapeutics Inc

Geschlossen

BrancheGesundheitswesen

2.31 -1.7

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

2.28

Max

2.42

Schlüsselkennzahlen

By Trading Economics

Einkommen

4.6M

24M

Verkäufe

13M

51M

KGV

Branchendurchschnitt

4.878

34.393

Gewinnspanne

46.203

Angestellte

119

EBITDA

4.9M

23M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+99.13% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

6. Nov. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

205M

377M

Vorheriger Eröffnungskurs

4.01

Vorheriger Schlusskurs

2.31

Nachrichtenstimmung

By Acuity

52%

48%

306 / 374 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bullish Evidence

CytomX Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

11. Aug. 2025, 17:49 UTC

Wichtige Markttreiber

180 Life Sciences Stock Jumps on $156 Million Notes Sale

11. Aug. 2025, 17:18 UTC

Wichtige Markttreiber

Tiziana Life Sciences Rises After FDA Approves IND for Foralumab Trial

11. Aug. 2025, 16:25 UTC

Ergebnisse

Correction to Constellation Software 2Q Revenue Rises, Profit Shrinks Article on Aug. 8

11. Aug. 2025, 23:50 UTC

Market Talk

Nikkei May Rise as Yen Weakens -- Market Talk

11. Aug. 2025, 23:42 UTC

Market Talk

Global Energy Roundup: Market Talk

11. Aug. 2025, 23:42 UTC

Market Talk

Woodside's Share Price Implies Lofty Oil Price -- Market Talk

11. Aug. 2025, 23:36 UTC

Market Talk

Gold Edges Higher on Likely Technical Recovery -- Market Talk

11. Aug. 2025, 23:32 UTC

Market Talk

Argosy's New Bull Sees Sentiment Toward REITs Improving -- Market Talk

11. Aug. 2025, 23:02 UTC

Market Talk

RBA Set to Lower OCR With New Forecasts in Focus -- Market Talk

11. Aug. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

11. Aug. 2025, 20:37 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Bakkt Holdings: Andy Main Will Step Dn as Co-CEO and Director, Effective Aug 11, and Akshay Naheta Will Assume Role of CEO >BKKT

11. Aug. 2025, 20:37 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Bakkt Holdings 2Q Rev $577.9M >BKKT

11. Aug. 2025, 20:37 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Bakkt Holdings: In Upcoming Qtr, Will Conduct Comprehensive Review of Cost Structure to Ensure We Are Optimized, Driving Synergies Across Business, and Accelerating Path to Profitability >BKKT

11. Aug. 2025, 20:22 UTC

Ergebnisse

Exodus Movement: Assets 2,058 Units of Bitcoin Valued at $220.5M, 2,729 Units of Ether Valued at $6.8M, $58.1M in Cash and Cash Equivalents, USD Coin, Treasury Bills as of June 30 >EXOD

11. Aug. 2025, 20:22 UTC

Ergebnisse

Exodus Movement: Monthly Active Users 1.5M at End 2Q, Unchanged From 1.5M as of June 30, 2024 >EXOD

11. Aug. 2025, 20:22 UTC

Ergebnisse

Exodus Movement: Processed Volume $1.38B in 2Q Dn 37% From 1Q, Bitcoin, Tether (TRX Network), Tether (ETH Network), USDC, SOL Top Assets Traded in 2Q >EXOD

11. Aug. 2025, 20:22 UTC

Ergebnisse

Exodus Movement: Digital Assets and Liquid Assets $291.2M >EXOD

11. Aug. 2025, 20:22 UTC

Ergebnisse

Exodus Movement 2Q Rev $25.8M >EXOD

11. Aug. 2025, 20:14 UTC

Market Talk

Canada Dollar Faces Near-Term Weakness on Trade Row, September Rate-Cut Chatter -- Market Talk

11. Aug. 2025, 19:12 UTC

Market Talk

Crude-Oil Futures Edge Up in Rangebound Trade -- Market Talk

11. Aug. 2025, 18:56 UTC

Market Talk

U.S. Natural-Gas Futures Fall on Forecast Loss of Late August Heat -- Market Talk

11. Aug. 2025, 18:31 UTC

Market Talk

Mining Halt Could Lift Lithium Prices in Near Term -- Market Talk

11. Aug. 2025, 17:43 UTC

Market Talk

Freeport-McMoRan Can Push Up Prices, Profits With Copper Tariff Protection -- Market Talk

11. Aug. 2025, 17:28 UTC

Market Talk

Crossborder Trade Tensions Accelerate Softness in Canada Rents -- Market Talk

11. Aug. 2025, 17:16 UTC

Market Talk

Commodity Longs Fall to 11-Month Low -- Market Talk

11. Aug. 2025, 16:42 UTC

Akquisitionen, Fusionen, Übernahmen

Adobe Stock Gets a Downgrade. 'AI Is Eating Software,' Analyst Says. -- Barrons.com

11. Aug. 2025, 16:27 UTC

Akquisitionen, Fusionen, Übernahmen

BBVA Says Sabadell Offer Remains in Effect

11. Aug. 2025, 16:26 UTC

Akquisitionen, Fusionen, Übernahmen

BBVA Previously Said It Won't Withdraw Offer to Buy Sabadell

11. Aug. 2025, 16:25 UTC

Akquisitionen, Fusionen, Übernahmen

Banco de Sabadell Announced TSB Sale on July 1

11. Aug. 2025, 16:25 UTC

Akquisitionen, Fusionen, Übernahmen

Banco de Sabadell Shareholders Approved TSB Unit Sale on Aug 6

Peer-Vergleich

Kursveränderung

CytomX Therapeutics Inc Prognose

Kursziel

By TipRanks

99.13% Vorteil

12-Monats-Prognose

Durchschnitt 4.6 USD  99.13%

Hoch 7 USD

Tief 2.5 USD

Basierend auf 5 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für CytomX Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

5 ratings

4

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

0.7658 / N/AUnterstützung & Widerstand

Kurzfristig

Strong Bullish Evidence

Mittelfristig

Very Strong Bullish Evidence

Langfristig

Weak Bullish Evidence

Stimmung

By Acuity

306 / 374 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bärische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über CytomX Therapeutics Inc

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.